Corpus Intelligence IC Memo — BAPTIST HEALTH SYSTEM 2026-04-26 04:04 UTC
IC Memo — BAPTIST HEALTH SYSTEM
Investment Committee Memorandum | TX | 1498 beds | Grade C | EBITDA uplift $97.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BAPTIST HEALTH SYSTEM

CCN 450058 | BEXAR, TX | 1498 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BAPTIST HEALTH SYSTEM is a 1498-bed large academic medical center in BEXAR, TX with $1.32B in net patient revenue and a 13.7% operating margin. The hospital serves a payer mix of 15.3% Medicare, 8.8% Medicaid, and 75.8% commercial.

Thesis: Platform Growth. Our ML models identify $97.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 13.7% to 21.1% (+736bps).

Net Revenue HCRIS$1.32B
Current EBITDA COMPUTED$180.8M
Operating Margin COMPUTED13.7%
Occupancy HCRIS52.5%
Revenue / Bed COMPUTED$879K
Net-to-Gross HCRIS10.6%
Distress Probability ML51.2%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
10
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 13.7% places it above the state median. Among 10 size-comparable peers (749-2996 beds), the median margin is 4.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (749-2996), prioritizing same-state peers. 10 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BAPTIST HEALTH SYSTEM (Target)TX1498$1.32B13.7%
MEMORIAL HERMANN TEXAS MEDICALTX1089$2.64B2.8%
THE METHODIST HOSPITALTX966$2.63B5.2%
TEXAS CHILDRENS HOSPITALTX863$2.50B-29.9%
METHODIST HOSPITALTX1729$2.42B22.9%
MEMORIAL HERMANN HOSPITAL SYSTX1417$2.15B7.3%
MEDICAL CITY DALLASTX819$1.33B49.7%
BAYLOR UNIVERSITY MEDICAL CTRTX800$1.26B0.4%
THE UNIVERSITY OF TEXAS MEDICATX819$1.19B-29.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $97.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$27.7M+210bp18mo
Cost to Collect4.5%2.5%$26.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$26.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$16.0M+122bp9mo
Clean Claim Rate88.0%96.0%$843K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$27.7M
Cost to Collect
$26.3M
Denial Rate Reduction
$26.1M
A/R Days Reduction
$16.0M
Clean Claim Rate
$843K
Total EBITDA Uplift$97.0M
Current EBITDA$180.8M
+ RCM Uplift+$97.0M
Pro Forma EBITDA$277.8M
Current Margin13.7%
Pro Forma Margin21.1%
WC Released (1x)$50.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$278.2M$2.16B7.77x50.7%
Base (11x exit)10.0x11.0x$278.2M$2.47B8.88x54.8%
Bull Case9.0x11.0x$250.4M$2.88B11.50x63.0%
Bull (12x exit)9.0x12.0x$250.4M$3.21B12.84x66.6%
Bear Case11.0x10.0x$306.0M$1.59B5.19x39.0%
Bear (11x exit)11.0x11.0x$306.0M$1.85B6.03x43.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighElevated distress probabilityModel estimates 51.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 10 hospitals with 749-2996 beds
  • Same-state prioritization (n=11)
  • Comp margins: P25=-22.3% / P50=4.0% / P75=11.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.